Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950360 | 0.88 | GRM2 (0.41) | DRD2GRM2MEN1KMT2ADRD4 | |
| SCHEMBL4946130 | 0.86 | GRM2 (0.52) | DRD2GRM2DRD4CHRM4 | |
| SCHEMBL4947684 | 0.84 | GRM2 (0.54) | DRD2GRM2DRD4 | |
| SCHEMBL4943381 | 0.83 | DRD2 (0.44) | DRD2GRM2DRD4MAPK1CHRM4 | |
| SCHEMBL4949378 | 0.83 | DRD2 (0.47) | DRD2GRM2DRD4CHRM4 | |
| SCHEMBL4943868 | 0.81 | DRD2 (0.51) | DRD2GRM2MEN1KMT2ADRD4 | |
| SCHEMBL4950382 | 0.80 | DRD2 (0.56) | DRD2GRM2MEN1KMT2ADRD4 | |
| SCHEMBL4948946 | 0.80 | DRD2 (0.44) | DRD2GRM2DRD4 | |
| SCHEMBL4949187 | 0.80 | DRD2 (0.46) | DRD2GRM2MEN1KMT2ADRD4 | |
| SCHEMBL4947832 | 0.80 | DRD2 (0.48) | DRD2GRM2MEN1KMT2ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | claimed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2007018998-A2 | TRICYCLIC BENZIMIDAZOLES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | DRD2 51/4885GRM2 1/4885MEN1 4375/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | DRD2 51/4885GRM2 1/4885MEN1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.